Endocrinology and Metabolism

Original Article

Diabetes, obesity and metabolism
Effects of an Electronic Medical Records-Linked Diabetes Self-Management System on Treatment Targets in Real Clinical Practice: Retrospective, Observational Cohort Study: So Jung Yang, Sun-Young Lim, Yoon Hee Choi, Jin Hee Lee, Kun-Ho Yoon; Endocrinol Metab. 2024;39(2):364-374. Published online March 21, 2024; DOI: https://doi.org/10.3803/EnM.2023.1878; Correction in: Endocrinol Metab 2024;39(3):537

8,222 View
122 Download
3 Web of Science
3 Crossref

Abstract PDF Supplementary Material PubReader ePub

Background
This study evaluated the effects of a mobile diabetes management program called “iCareD” (College of Medicine, The Catholic University of Korea) which was integrated into the hospital’s electronic medical records system to minimize the workload of the healthcare team in the real clinical practice setting.
Methods
In this retrospective observational study, we recruited 308 patients. We categorized these patients based on their compliance regarding their use of the iCareD program at home; compliance was determined through self-monitored blood glucose inputs and message subscription rates. We analyzed changes in the ABC (hemoglobin A1c, blood pressure, and low-density lipoprotein cholesterol) levels from the baseline to 12 months thereafter, based on the patients’ iCareD usage patterns.
Results
The patients comprised 92 (30%) non-users, 170 (55%) poor-compliance users, and 46 (15%) good-compliance users; the ABC target achievement rate showed prominent changes in good-compliance groups from baseline to 12 months (10.9% vs. 23.9%, P<0.05), whereas no significant changes were observed for poor-compliance users and non-users (13.5% vs. 18.8%, P=0.106; 20.7% vs. 14.1%, P=0.201; respectively).
Conclusion
Implementing the iCareD can improve the ABC levels of patients with diabetes with minimal efforts of the healthcare team in real clinical settings. However, the improvement of patients’ compliance concerning the use of the system without the vigorous intervention of the healthcare team needs to be solved in the future.

Citations

Citations to this article as recorded by

Stakeholder Perspectives on Implementing DiabeText: Exploring Barriers and Facilitators for a Personalized Diabetes Self-Management SMS Intervention in Spain
Elena Gervilla-García, Patricia García-Pazo, Mireia Guillén-Solà, Federico Leguizamo, Ignacio Ricci-Cabello, María Jesús Serrano-Ripoll, Miquel Bennasar-Veny, Maria Antònia Fiol-deRoque, Escarlata Angullo-Martínez, Rocío Zamanillo-Campos
Diabetology.2026; 7(1): 17. CrossRef
Addressing Unmet Needs in the Management of Diabetes in Asia and Enhancing Diabetes Care Through the Use of Digital Technology:
Daphne Gardner, Julia K. Mader, Sanjay Kalra, Irene Kopp, Banshi Saboo, Kazuhiro Sugimoto, Michael Villa, Shailendra Bajpai
Journal of the ASEAN Federation of Endocrine Societies.2026;[Epub] CrossRef
Implementation of health technology in Asia: A scoping review
Yee Shin Carlyne Li, Jong Yi Foo, Chong Yau Ong
Digital Medicine.2026; 12(2): e25-00010. CrossRef

Review Articles

Thyroid
Management of Subclinical Hypothyroidism: A Focus on Proven Health Effects in the 2023 Korean Thyroid Association Guidelines: Eu Jeong Ku, Won Sang Yoo, Hyun Kyung Chung; Endocrinol Metab. 2023;38(4):381-391. Published online August 8, 2023; DOI: https://doi.org/10.3803/EnM.2023.1778

23,996 View
881 Download
8 Web of Science
13 Crossref

Abstract PDF PubReader ePub

Subclinical hypothyroidism (SCH) is characterized by elevated thyroid-stimulating hormone (TSH) and normal free thyroxine levels. The Korean Thyroid Association recently issued a guideline for managing SCH, which emphasizes Korean-specific TSH diagnostic criteria and highlights the health benefits of levothyroxine (LT4) treatment. A serum TSH level of 6.8 mIU/L is presented as the reference value for diagnosing SCH. SCH can be classified as mild (TSH 6.8 to 10.0 mIU/L) or severe (TSH >10.0 mIU/L), and patients can be categorized as adults (age <70 years) or elderly (age ≥70 years), depending on the health effects of LT4 treatment. An initial increase in serum TSH levels should be reassessed with a subsequent measurement, including a thyroid peroxidase antibody test, preferably 2 to 3 months after the initial assessment. While LT4 treatment is not generally recommended for mild SCH in adults, it is necessary for severe SCH in patients with underlying coronary artery disease or heart failure and it may be considered for those with concurrent dyslipidemia. Conversely, LT4 treatment is generally not recommended for elderly patients, regardless of SCH severity. For those SCH patients who are prescribed LT4 treatment, the dosage should be personalized, and serum TSH levels should be regularly monitored to maintain the optimal LT4 regimen.

Citations

Citations to this article as recorded by

Sex differences in prevalence of subclinical hypothyroidism and its clinical correlates in overweight or obese, first-episode drug-naïve Chinese patients with major depressive disorder
Qiyue Qiu, Wan Yin Tew, Chenxi Liu, Jie Zhang, Bo Liu, Mun Fei Yam, Shichang Yang, Xiang-Yang Zhang
Journal of Affective Disorders.2026; 398: 121068. CrossRef
Assessment of Serum Adropin Levels in Patients with Subclinical Hypothyroidism
Tuba Yılmaz Yıldırım, Mehmet Zorlu, Eray Metin Güler, Muharrem Kıskaç, Hakan Beyaztaş
Bezmialem Science.2026;[Epub] CrossRef
Evaluation of the add on effect of Majoone Sarkhas with levothyroxine in primary hypothyroidism: a randomized standard control adjuvant clinical study
Md Anzar Alam, Mohd Aleemuddin Quamri, Ghulamuddin Sofi, Nafis Haider
Drug Metabolism and Personalized Therapy.2025; 40(2): 121. CrossRef
Macro-Thyrotropin Syndrome: Prevalence and Clinical Profile of an Under-Recognised Rare Entity in Thyroidology
Maitri M. Patel, Dhara K. Patel, Lalitkumar B. Patel, Chetan B. Dharaiya, Dhruvkumar M. Patel, Ravi M. Vasani, Mukundkumar V. Patel
Indian Journal of Endocrinology and Metabolism.2025; 29(1): 95. CrossRef
Long-term forecasting and evaluation of medicine consumption for the ATC class H with a focus on thyroid hormones in OECD countries using ARIMA models
Lilly Josephine Bindel, Roland Seifert
Naunyn-Schmiedeberg's Archives of Pharmacology.2025; 398(8): 10691. CrossRef
Incidence and risk factors for early thyroxin supplementation therapy after hemithyroidectomy for benign conditions in Europe. A Eurocrine® registry-based study
Jesús M. Villar-del-Moral, Juan I. Arcelus-Martínez, Antonio Becerra-Massare, Nuria Muñoz-Pérez, María C. Olvera-Porcel, Cristina Martínez-Santos
Updates in Surgery.2025; 77(5): 1593. CrossRef
DIAGNÓSTICO E MANEJO DO HIPOTIREOIDISMO SUBCLÍNICO: UMA REVISÃO DE LITERATURA
Dayane Beserra Costa Felício, Mariana Barbosa Silva, Mileide Beatriz de Lima Santos, Yasmin Cabral Menezes de Oliveira, Vinícius de Lima Paes, Ana Paula Simadon, Cleyciane Camila de Souza Belo Nogueira, Giulia Costa Moura
REVISTA FOCO.2025; 18(4): e8209. CrossRef
Subclinical Hypothyroidism after a Three-Month Course of Low-Dose Amiodarone.
Rano Kirkimbayeva, Telman Seisembekov, Bakyt Iskakova, Nauryzbay Bekishuly, Assel Chinybayeva, Galiya Smailova, Diana Aibulova, Aya Aitpayeva, Aidana Butabayeva, Zhansaya Yerkhanova, Olzhas Yesseneyev, Ayan Abdrakhmanov
Journal of Clinical Medicine of Kazakhstan.2025; 22(2): 54. CrossRef
Impact of subclinical hypothyroidism on glycemic markers and insulin resistance in nondiabetic Iraqi patients: a cross-sectional study
Maysam Riyadh Mohammed Hussein Alaasam, Raffat Hilal Abboodi, Hayder Nadhim Mohsin Al-Khayyat
INTERNATIONAL JOURNAL OF ENDOCRINOLOGY (Ukraine).2025; 21(6): 583. CrossRef
Clinical Implications of Different Thyroid-Stimulating Hormone (TSH) Reference Intervals between TSH Kits for the Management of Subclinical Hypothyroidism
Won Sang Yoo
Endocrinology and Metabolism.2024; 39(1): 188. CrossRef
Serum Vitamin B12 and Holotranscobalamin Levels in Subclinical Hypothyroid Patients in Relation to Thyroid-Stimulating Hormone (TSH) Levels and the Positivity of Anti-thyroid Peroxidase Antibodies: A Case-Control Study
Muqdad Al-Mousawi, Sherwan Salih, Ameer Ahmed, Barhav Abdullah
Cureus.2024;[Epub] CrossRef
Severe Symptomatic Anemia as a Rare Initial Manifestation of Type 3 Polyglandular Autoimmune Syndrome: A Case Report
Hugo Goncalves, Francisco De Oliveira Simões, Rosa Sá, Bárbara Fraga Campos, Rui M Domingues, Narciso Oliveira, Teresa Pimentel
Cureus.2024;[Epub] CrossRef
Evaluation of the effects of thyroid functions on frailty in geriatric patients using the Edmonton, SOF and FRAIL Scales
Galip Can Uyar, Mustafa Kemal Kılıç
BMC Geriatrics.2024;[Epub] CrossRef

Diabetes, Obesity and Metabolism
Extra-Glycemic Effects of Anti-Diabetic Medications: Two Birds with One Stone?: Eun-Jung Rhee; Endocrinol Metab. 2022;37(3):415-429. Published online June 29, 2022; DOI: https://doi.org/10.3803/EnM.2022.304

10,846 View
358 Download
5 Web of Science
5 Crossref

Abstract PDF PubReader ePub

The world is suffering from a rapid increase in the number of people with diabetes due to the increased prevalence of obesity and lengthened life span. Since the development of insulin thanks to the efforts of Prof. Banting and Dr. Best in 1922, for which they won the Nobel Prize, remarkable developments in anti-diabetic medications have dramatically lengthened the lifespan of patients with diabetes. However, the control rate of hyperglycemia in patients with diabetes remains unsatisfactory, since glycemic control requires both medication and lifestyle modifications to slow the deterioration of pancreatic beta-cell function and prevent diabetic complications. From the initial “triumvirate” to the “ominous octet,” and now the “egregious eleven,” the number of organs recognized as being involved in hyperglycemia and diabetes has increased with the development of anti-diabetic medications. Recent unexpected results from outcome trials of anti-diabetic medications have enabled anti-diabetic medications to be indicated for the prevention of chronic kidney disease and heart failure, even in patients without diabetes. In this review, I would like to summarize the extra-glycemic effects of anti-diabetic medications.

Citations

Citations to this article as recorded by

Antidiabetic Agents as Antioxidant and Anti-Inflammatory Therapies in Neurological and Cardiovascular Diseases
Snehal Raut, Luca Cucullo
Antioxidants.2025; 14(12): 1490. CrossRef
Spectrum of effects of dipeptidyl peptidase-4 inhibitors: within and beyond glycemic control (part 2)
L. A. Ruyatkina, D. S. Ruyatkin
Diabetes mellitus.2025; 28(5): 451. CrossRef
Association between underweight and risk of heart failure in diabetes patients
Tae Kyung Yoo, Kyung‐Do Han, Eun‐Jung Rhee, Won‐Young Lee
Journal of Cachexia, Sarcopenia and Muscle.2024; 15(2): 671. CrossRef
Glucagon-Like Peptide Receptor Agonist Inhibits Angiotensin II-Induced Proliferation and Migration in Vascular Smooth Muscle Cells and Ameliorates Phosphate-Induced Vascular Smooth Muscle Cells Calcification
Jinmi Lee, Seok-Woo Hong, Min-Jeong Kim, Sun Joon Moon, Hyemi Kwon, Se Eun Park, Eun-Jung Rhee, Won-Young Lee
Diabetes & Metabolism Journal.2024; 48(1): 83. CrossRef
To do one and to get more: Part I. Diabetes and bone
Wen-Ling Lee, Peng-Hui Wang, Szu-Ting Yang, Chia-Hao Liu, Wen-Hsun Chang, Fa-Kung Lee
Journal of the Chinese Medical Association.2022; 85(10): 965. CrossRef

Thyroid
T4+T3 Combination Therapy: An Unsolved Problem of Increasing Magnitude and Complexity: Wilmar M. Wiersinga; Endocrinol Metab. 2021;36(5):938-951. Published online September 30, 2021; DOI: https://doi.org/10.3803/EnM.2021.501

33,442 View
499 Download
21 Web of Science
17 Crossref

Abstract PDF PubReader ePub

Thyroxine (T4)+triiodothyronine (T3) combination therapy can be considered in case of persistent symptoms despite normal serum thyroid stimulating hormone in levothyroxine (LT4)-treated hypothyroid patients. Combination therapy has gained popularity in the last two decades, especially in countries with a relatively high gross domestic product. The prevalence of persistent symptoms has also increased; most frequent are complaints about energy levels and fatigue (80% to 90%), weight management (70% to 75%), memory (60% to 80%), and mood (40% to 50%). Pathophysiological explanations for persistent problems are unrealistic patient expectations, comorbidities, somatic symptoms, related disorders (Diagnostic and Statistical Manual of Mental Disorders [DSM-5]), autoimmune neuroinflammation, and low tissue T3. There is fair circumstantial evidence for the latter cause (tissue and specifically brain T3 content is normalized by T4+T3, not by T4 alone), but the other causes are viewed as more relevant in current practice. This might be related to the ‘hype’ that has emerged surrounding T4+T3 therapy. Although more and better-designed trials are needed to validate the efficacy of T4+T3 combination, the management of persistent symptoms should also be directed towards alternative causes. Improving the doctor-patient relationship and including more and better information is crucial. For example, dissatisfaction with the outcomes of T4 treatment for subclinical hypothyroidism can be anticipated as recent trials have demonstrated that LT4 is hardly effective in improving symptoms associated with subclinical hypothyroidism.

Citations

Citations to this article as recorded by

Hemodialysis Tends to Improve Thyroid Function by Restoring Hormone Levels in ESRD Patients Compared to Non-Dialysis Kidney Disease Patients: A Case–Control Study
Hasibul Islam, Shahad Saif Khandker, Anwara Khatun, Ehsan Suez, Alif Hasan Pranto, Dewan Zubaer Islam, Rahima Begum, Md. Nizam Uddin, Md. Ashraful Hasan, Md. Shah Alam, A. N. M. Mamun-Or-Rashid
Diseases.2026; 14(4): 128. CrossRef
Developing a machine learning-based predictive model for levothyroxine dosage estimation in hypothyroid patients: a retrospective study
Tran Thi Ngan, Dang Huong Tra, Ngo Thi Quynh Mai, Hoang Van Dung, Nguyen Van Khai, Pham Van Linh, Nguyen Thi Thu Phuong
Frontiers in Endocrinology.2025;[Epub] CrossRef
Thyroid hormone use in clinical practice by Israeli endocrinologists: a THESIS* questionnaire survey
Liat Sasson, Keren Kaminer, Chagit Adler Cohen, Laszlo Hegedüs, Roberto Negro, Endre V. Nagy, Enrico Papini, Petros Perros, Roberto Attanasio, Eyal Robenshtok
Thyroid Research.2025;[Epub] CrossRef
Advances in hypothyroidism management: rethinking therapy beyond levothyroxine
R Ditshego, J Pick, KN Ncube
SA Pharmaceutical Journal.2025; 92(4): 50. CrossRef
Association of DIO2 and MCT10 Polymorphisms With Persistent Symptoms in LT4-Treated Patients in the UK Biobank
Christian Zinck Jensen, Jonas Lynggaard Isaksen, Gustav Ahlberg, Morten Salling Olesen, Birte Nygaard, Christina Ellervik, Jørgen Kim Kanters
The Journal of Clinical Endocrinology & Metabolism.2024; 109(2): e613. CrossRef
Quality of life, daily functioning, and symptoms in hypothyroid patients on thyroid replacement therapy: A Dutch survey
Ellen Molewijk, Eric Fliers, Koen Dreijerink, Ad van Dooren, Rob Heerdink
Journal of Clinical & Translational Endocrinology.2024; 35: 100330. CrossRef
Cardiovascular mechanisms of thyroid hormones and heart failure: Current knowledge and perspectives
Viktor Čulić
World Journal of Cardiology.2024; 16(5): 226. CrossRef
Use of thyroid hormones in hypothyroid and euthyroid patients: A survey of members of the Endocrine Society of Australia
Nicole Lafontaine, Suzanne J. Brown, Petros Perros, Enrico Papini, Endre V. Nagy, Roberto Attanasio, Laszlo Hegedüs, John P. Walsh
Clinical Endocrinology.2024; 100(5): 477. CrossRef
Triiodothyronine levels in athyreotic pediatric patients during levothyroxine therapy
Julia Baran, Amber Isaza, Mya Bojarsky, Lama Alzoebie, Minkeun Song, Stephen Halada, Lindsay Sisko, Stephanie Gonzales, Sogol Mostoufi-Moab, Andrew J. Bauer
Frontiers in Endocrinology.2024;[Epub] CrossRef
Posttreatment symptoms in hypothyroidism and correlations with thyroid-stimulating hormone and free triiodothyronine and free thyroxine: A ThyPRO-based follow-up study
Ashika Davis, Jyothi Mariam Idiculla
Thyroid Research and Practice.2024; 20(2): 64. CrossRef
A review of the safety of triiodothyronine in combination with levothyroxine for the management of hypothyroidism
Ulrike Gottwald-Hostalek, Yorki Tayrouz
Current Medical Research and Opinion.2024; 40(12): 2109. CrossRef
Use of Thyroid Hormones in Hypothyroid and Euthyroid Patients: A THESIS questionnaire survey of members of the Irish Endocrine Society
Mohamad Mustafa, Elsheikh Ali, Anne McGowan, Laura McCabe, Laszlo Hegedüs, Roberto Attanasio, Endre V. Nagy, Enrico Papini, Petros Perros, Carla Moran
Irish Journal of Medical Science (1971 -).2023; 192(5): 2179. CrossRef
Levothyroxine: Conventional and Novel Drug Delivery Formulations
Hanqing Liu, Wei Li, Wen Zhang, Shengrong Sun, Chuang Chen
Endocrine Reviews.2023; 44(3): 393. CrossRef
Re: “Exploring the Genetic Link Between Thyroid Dysfunction and Common Psychiatric Disorders: A Specific Hormonal or a General Autoimmune Comorbidity” by Soheili-Nezhad et al.
Christiaan F. Mooij, A.S. Paul van Trotsenburg
Thyroid®.2023; 33(8): 999. CrossRef
Circulating thyroid hormones and clinical parameters of heart failure in men
Iva Turić, Ivan Velat, Željko Bušić, Viktor Čulić
Scientific Reports.2023;[Epub] CrossRef
Evaluation of cortical and trabecular bone structure of the mandible in patients using L-Thyroxine
Melike Gulec, Melek Tassoker, Mediha Erturk
BMC Oral Health.2023;[Epub] CrossRef
The Impact of Hypothyroidism on Satisfaction with Care and Treatment and Everyday Living: Results from E-Mode Patient Self-Assessment of Thyroid Therapy, a Cross-Sectional, International Online Patient Survey
Petros Perros, Laszlo Hegedüs, Endre Vezekenyi Nagy, Enrico Papini, Harriet Alexandra Hay, Juan Abad-Madroñero, Amy Johanna Tallett, Megan Bilas, Peter Lakwijk, Alan J. Poots
Thyroid.2022;[Epub] CrossRef

Adrenal gland
Is Follow-up of Adrenal Incidentalomas Always Mandatory?: Giuseppe Reimondo, Alessandra Muller, Elisa Ingargiola, Soraya Puglisi, Massimo Terzolo; Endocrinol Metab. 2020;35(1):26-35. Published online March 19, 2020; DOI: https://doi.org/10.3803/EnM.2020.35.1.26

16,180 View
310 Download
15 Web of Science
16 Crossref

Abstract PDF PubReader ePub

Adrenal masses are mainly detected unexpectedly by an imaging study performed for reasons unrelated to any suspect of adrenal diseases. Such masses are commonly defined as “adrenal incidentalomas” and represent a public health challenge because they are increasingly recognized in current medical practice. Management of adrenal incidentalomas is currently matter of debate. Although there is consensus on the need of a multidisciplinary expert team evaluation and surgical approach in patients with significant hormonal excess and/or radiological findings suspicious of malignancy demonstrated at the diagnosis or during follow-up, the inconsistency between official guidelines and the consequent diffuse uncertainty on management of small adrenal incidentalomas still represents a considerable problem in terms of clinical choices in real practice. The aim of the present work is to review the proposed strategies on how to manage patients with adrenal incidentalomas that are not candidates to immediate surgery. The recent European Society of Endocrinology/European Network for the Study of Adrenal Tumors guidelines have supported the view to avoid surveillance in patients with clear benign adrenal lesions <4 cm and/or without any hormonal secretion; however, newer prospective studies are needed to confirm safety of this strategy, in particular in younger patients.

Citations

Citations to this article as recorded by

Beyond the norm: Exploring the diverse facets of adrenal lesions
Sadaf Afif, Zoya Mahmood, Atif Zaheer, Javad R. Azadi
Current Problems in Diagnostic Radiology.2026; 55(1): 137. CrossRef
Incidental Adrenal Nodules and Growth Rates: A Single Centre Retrospective Cohort Study
Julie Hu, Remy Lim, Mark Bolland
Journal of Medical Imaging and Radiation Oncology.2026; 70(1): 50. CrossRef
Is muscle strength an overlooked parameter in patients affected by mild autonomous cortisol secretion?
Martina Romanisio, Chiara Mele, Sara Sturnia, Carola Ciamparini, Rosa Pitino, Alice Ferrero, Lorenza Scotti, Madalina Elena Iftimie, Gianluca Aimaretti, Paolo Marzullo, Flavia Prodam, Marina Caputo
Frontiers in Endocrinology.2026;[Epub] CrossRef
Imaging of Adrenal Incidentalomas: What Actually Happens in Everyday Clinical Practice?
Brian Ngo, Tracy Liu, Eddie Lau
Journal of Medical Imaging and Radiation Oncology.2025; 69(3): 328. CrossRef
The Landmark Series: Evaluation and Management of Adrenal Incidentalomas
Lily Owei, Heather Wachtel
Annals of Surgical Oncology.2025; 32(7): 4712. CrossRef
Prolonged symptom duration and the potential for gradual progression in pediatric adrenocortical tumors: observations from the MET studies
Michaela Kuhlen, Stefan A. Wudy, Clara Baumann, Christian Vokuhl, Michaela F. Hartmann, Marina Kunstreich, Rainer Claus, Antje Redlich
Journal of Pediatric Endocrinology and Metabolism.2025; 38(9): 931. CrossRef
Long-Term Follow-Up of Adrenal Incidentalomas: A Portuguese Single-Center Study
David Veríssimo, Beatriz Pereira, Joana Rodrigues, Catarina Ivo, Ana Cláudia Martins, João Nunes e Silva, Dolores Passos, Luís Lopes, João Jácome de Castro, Mafalda Marcelino
Endocrinology Insights.2025; 20(2): 67. CrossRef
Mineral Metabolism Assays, Central DXA, and Fracture Risk Probabilities in Menopausal Patients with Non-Functional Adrenal Tumors with/Without Mild Autonomous Cortisol Secretion: Does the Presence of Unilateral Versus Bilateral Tumors Matter?
Alexandra-Ioana Trandafir, Mara Carsote, Mihai Costachescu, Oana-Claudia Sima, Alexandru-Florin Florescu
Life.2025; 15(10): 1639. CrossRef
Case of adrenocortical cancer eleven years after diagnosis of adrenocortical adenoma
Aleksandr A. Lisitsyn, Vyacheslav P. Zemlianoy, Vadim I. Mazurov, Ludmila I. Velikanova, Irina A. Bekhtereva
Kazan medical journal.2025; 106(6): 1023. CrossRef
Adrenal Incidentaloma—Innocent Bystander or Intruder?
Laurence Amar, Inga Harbuz-Miller, Adina F Turcu
The Journal of Clinical Endocrinology & Metabolism.2024; 109(3): e1303. CrossRef
Mineral metabolism assays and osteoporotic fracture risk evaluation in menopausal population diagnosed with adrenal incidentalomas: a sub-analysis of PRECES study
Alexandra-Ioana Trandafir, Mihaela Stanciu, Ana Valea, Oana-Claudia Sima, Claudiu Nistor, Mădălina Gabriela Iliescu, Ileana Ciobanu, Florina Ligia Popa, Mara Carsote
Balneo and PRM Research Journal.2024; 15(Vol.15, no): 692. CrossRef
Diagnosing and managing adrenal incidentalomas
Justine Herndon, Irina Bancos
JAAPA.2023; 36(5): 12. CrossRef
Tumor enlargement in adrenal incidentaloma is related to glaucoma: a new prognostic feature?
M. Caputo, T. Daffara, A. Ferrero, M. Romanisio, E. Monti, C. Mele, M. Zavattaro, S. Tricca, A. Siani, A. Clemente, C. Palumbo, S. De Cillà, A. Carriero, A. Volpe, P. Marzullo, G. Aimaretti, F. Prodam
Journal of Endocrinological Investigation.2023; 47(2): 377. CrossRef
The Role of Biomarkers in Adrenocortical Carcinoma: A Review of Current Evidence and Future Perspectives
Maja Mizdrak, Tina Tičinović Kurir, Joško Božić
Biomedicines.2021; 9(2): 174. CrossRef
An Adrenocortical Carcinoma Evolving After Nine Years of Latency From a Small Adrenal Incidentaloma
Harpreet S Kohli, Sukesh Manthri, Shikha Jain, Rahul Kashyap, Sheng Chen, Thoyaja Koritala, Aysun Tekin, Ramesh Adhikari, Raghavendra Tirupathi, Aram Barbaryan, Simon Zec, Hanyin Wang, Stephanie Welle, Pavan Devulapally, Mack Sheraton, Manpreet Kaur, Vish
Cureus.2021;[Epub] CrossRef
Diagnostic algorithm of the subclinical forms of adrenal neoplasms
Sofya G. Blyumina, Pavel N. Romashchenko, Igor S. Zheleznyak
Bulletin of the Russian Military Medical Academy.2021; 23(3): 67. CrossRef

Original Articles

Plasma Angiotensin - Converting Enzyme Activity, NAG, Renin and Atrial Natriuretic Peptide in Korean Male Subjects.: Jin Hong Lee, Suhn Hee Kim, Ho Shin Song, Sang Hun Han, Kyung Woo Cho, Gou Young Koh; J Korean Endocr Soc. 1994;9(1):18-24. Published online November 6, 2019

1,771 View
20 Download

Abstract PDF: The purpose of the present study was to define the normal range of plasma concentration of angiotensin I-converting enzyme(ACE), N-acetyl-b-D-glucosaminidase(NAG), inactive and active renin, and atrial natriuretic peptide(ANP) in normal Korean adult male in terms of aging. Both plasma ACE activity and NAG concentration were measured by spectrofluorometry, and the plasma renin activity and ANP concentration were measured using radioimmunoassay. The ACE was 67.7+-3.6 nM His-Leu/min/ml and did not change in terms of age. The plasma NAG activity tended to decrease. Both plasma active and inactive renin activities were 2.1+-0.2 and 3.0+-0.3 ngAI/ml/h and tended to decrease in terms of aging. The percentage of inactive renin to total renin was 57.2+-2.9% at age 21-30 and also tended to decrease in terms of aging. Plasma ANP concentration at age 22 was 59.6+-2.9 pg/ml.

Clinical Study
Effects of Dipeptidyl Peptidase-4 Inhibitors on Hyperglycemia and Blood Cyclosporine Levels in Renal Transplant Patients with Diabetes: A Pilot Study: Jaehyun Bae, Min Jung Lee, Eun Yeong Choe, Chang Hee Jung, Hye Jin Wang, Myoung Soo Kim, Yu Seun Kim, Joong-Yeol Park, Eun Seok Kang; Endocrinol Metab. 2016;31(1):161-167. Published online March 16, 2016; DOI: https://doi.org/10.3803/EnM.2016.31.1.161

10,085 View
71 Download
24 Web of Science
25 Crossref

Abstract PDF PubReader

Background

The use of dipeptidyl peptidase-4 (DPP-4) inhibitors is increasing among renal transplant patients with diabetes. However, the glucose-lowering efficacies of various DPP-4 inhibitors and their effects on blood cyclosporine levels have not been fully investigated. We compared the glucose-lowering efficacies of DPP 4 inhibitors and evaluate their effects on the blood levels of cyclosporine in renal transplant recipients with diabetes.

Methods

Sixty-five renal allograft recipients who received treatment with DPP-4 inhibitors (vildagliptin, sitagliptin, or linagliptin) following kidney transplant were enrolled. The glucose-lowering efficacies of the DPP-4 inhibitors were compared according to the changes in the hemoglobin A1c (HbA1c) levels after 3 months of treatment. Changes in the trough levels of the cyclosporine were also assessed 2 months after treatment with each DPP-4 inhibitor.

Results

HbA1c significantly decreased in the linagliptin group in comparison with other DPP-4 inhibitors (vildagliptin –0.38%±1.03%, sitagliptin –0.53%±0.95%, and linagliptin –1.40±1.34; P=0.016). Cyclosporine trough levels were significantly increased in the sitagliptin group compared with vildagliptin group (30.62±81.70 ng/mL vs. –24.22±53.54 ng/mL, P=0.036). Cyclosporine trough levels were minimally changed in patients with linagliptin.

Conclusion

Linagliptin demonstrates superior glucose-lowering efficacy and minimal effect on cyclosporine trough levels in comparison with other DPP-4 inhibitors in kidney transplant patients with diabetes.

Citations

Citations to this article as recorded by

Post-transplant metabolic dysregulation: Insights and implications for kidney graft survival
Tabassum Elahi, Saima Ahmed, Muhammed Mubarak
World Journal of Nephrology.2026;[Epub] CrossRef
Comparison of Clinical Outcomes Between Two Types of Dipeptidyl Peptidase-4 Inhibitors in Posttransplant Diabetes Mellitus in Kidney Transplantation Recipients: A Nationwide Population-Based Cohort Study in Korea
Keun young Lee, Ga young Song, Min jun Seo, Sung hwa Kim, Dae Ryong Kang, Keunryul Park, Ji Teck Kim, Sang Wook Park, Jun Young Lee
Transplantation Proceedings.2025; 57(2): 208. CrossRef
Endocrine effects of long-term calcineurin inhibitor use in solid organ transplant recipients
Talia Diker Cohen, Idit Dotan, Bronya Calvarysky, Eyal Robenshtok
European Journal of Endocrinology.2025; 193(3): R1. CrossRef
Comparative efficacy and safety of antidiabetic agents for post-transplant diabetes mellitus: a network meta-analysis
Shanbiao Hu, Gongbin Lan
Frontiers in Medicine.2025;[Epub] CrossRef
Diabetic Kidney Disease in Post-Kidney Transplant Patients
Ngoc-Yen T. Pham, Diego Cruz, Luis Madera-Marin, Raja Ravender, Pablo Garcia
Journal of Clinical Medicine.2024; 13(3): 793. CrossRef
International consensus on post-transplantation diabetes mellitus
Adnan Sharif, Harini Chakkera, Aiko P J de Vries, Kathrin Eller, Martina Guthoff, Maria C Haller, Mads Hornum, Espen Nordheim, Alexandra Kautzky-Willer, Michael Krebs, Aleksandra Kukla, Amelie Kurnikowski, Elisabeth Schwaiger, Nuria Montero, Julio Pascual
Nephrology Dialysis Transplantation.2024; 39(3): 531. CrossRef
Metabolic Disorders in Liver Transplant Recipients: The State of the Art
Filippo Gabrielli, Lucia Golfieri, Fabio Nascimbeni, Pietro Andreone, Stefano Gitto
Journal of Clinical Medicine.2024; 13(4): 1014. CrossRef
Diabetic Kidney Disease in Post-Transplant Diabetes Mellitus: Causes, Treatment and Outcomes
Lee-Moay Lim, Jer-Ming Chang, Hung-Tien Kuo
Biomedicines.2023; 11(2): 470. CrossRef
Sweet and simple as syrup: A review and guidance for use of novel antihyperglycemic agents for post‐transplant diabetes mellitus and type 2 diabetes mellitus after kidney transplantation
S. Elise Lawrence, Mary Moss Chandran, Jeong M. Park, Helen Sweiss, Thomas Jensen, Palak Choksi, Barrett Crowther
Clinical Transplantation.2023;[Epub] CrossRef
Interventions Against Posttransplantation Diabetes: A Scientific Rationale for Treatment Hierarchy Based on Literature Review
Adnan Sharif
Transplantation.2022; 106(12): 2301. CrossRef
Dipeptidyl Peptidase-4 Inhibitor Decreases Allograft Vasculopathy Via Regulating the Functions of Endothelial Progenitor Cells in Normoglycemic Rats
Feng-Yen Lin, Chun-Min Shih, Chun-Yao Huang, Yi-Tin Tsai, Shih-Hurng Loh, Chi-Yuan Li, Cheng-Yen Lin, Yi-Wen Lin, Chien-Sung Tsai
Cardiovascular Drugs and Therapy.2021; 35(6): 1111. CrossRef
Review of Newer Antidiabetic Agents for Diabetes Management in Kidney Transplant Recipients
Sonya Anderson, Laura Cotiguala, Sarah Tischer, Jeong Mi Park, Katie McMurry
Annals of Pharmacotherapy.2021; 55(4): 496. CrossRef
Incretin based therapies and SGLT-2 inhibitors in kidney transplant recipients with diabetes: A systematic review and meta-analysis
Dora Oikonomaki, Evangelia Dounousi, Anila Duni, Stefanos Roumeliotis, Vassilios Liakopoulos
Diabetes Research and Clinical Practice.2021; 172: 108604. CrossRef
CD161a-positive natural killer (NK) cells and α-smooth muscle actin-positive myofibroblasts were upregulated by extrarenal DPP4 in a rat model of acute renal rejection
Franziska Schmid, Christina Mayer, Maike Büttner-Herold, Stephan von Hörsten, Kerstin Amann, Christoph Daniel
Diabetes Research and Clinical Practice.2021; 173: 108691. CrossRef
Current Pharmacological Intervention and Medical Management for Diabetic Kidney Transplant Recipients
Theerawut Klangjareonchai, Natsuki Eguchi, Ekamol Tantisattamo, Antoney J. Ferrey, Uttam Reddy, Donald C. Dafoe, Hirohito Ichii
Pharmaceutics.2021; 13(3): 413. CrossRef
Recent advances in new-onset diabetes mellitus after kidney transplantation
Tess Montada-Atin, G V Ramesh Prasad
World Journal of Diabetes.2021; 12(5): 541. CrossRef
Safety and Efficacy of Long-Term Administration of Dipeptidyl peptidase IV Inhibitors in Patients With New Onset Diabetes After Kidney Transplant
Adamantia Mpratsiakou, Marios Papasotiriou, Theodoros Ntrinias, Konstantinos Tsiotsios, Evangelos Papachristou, Dimitrios S. Goumenos
Experimental and Clinical Transplantation.2021; 19(5): 411. CrossRef
Medical management of metabolic and cardiovascular complications after liver transplantation
Chiara Becchetti, Melisa Dirchwolf, Vanessa Banz, Jean-François Dufour
World Journal of Gastroenterology.2020; 26(18): 2138. CrossRef
Efficacy and Safety of Dipeptidyl Peptidase-4 Inhibitors in Kidney Transplant Recipients with Post-transplant Diabetes Mellitus (PTDM)- a Systematic Review and Meta-Analysis
Tarek Samy Abdelaziz, Ahmed Yamany Ali, Moataz Fatthy
Current Diabetes Reviews.2020; 16(6): 580. CrossRef
NAFLD and liver transplantation: Disease burden, current management and future challenges
Patrizia Burra, Chiara Becchetti, Giacomo Germani
JHEP Reports.2020; 2(6): 100192. CrossRef
Linagliptin plus insulin for hyperglycemia immediately after renal transplantation: A comparative study
Rodolfo Guardado-Mendoza, David Cázares-Sánchez, María Lola Evia-Viscarra, Lilia M. Jiménez-Ceja, Edgar G. Durán-Pérez, Alberto Aguilar-García
Diabetes Research and Clinical Practice.2019; 156: 107864. CrossRef
Post-Liver Transplantation Diabetes Mellitus: A Review of Relevance and Approach to Treatment
Maria J. Peláez-Jaramillo, Allison A. Cárdenas-Mojica, Paula V. Gaete, Carlos O. Mendivil
Diabetes Therapy.2018; 9(2): 521. CrossRef
Articles inEndocrinology and Metabolismin 2016
Won-Young Lee
Endocrinology and Metabolism.2017; 32(1): 62. CrossRef
Drug–drug interactions between immunosuppressants and antidiabetic drugs in the treatment of post-transplant diabetes mellitus
Thomas Vanhove, Quinten Remijsen, Dirk Kuypers, Pieter Gillard
Transplantation Reviews.2017; 31(2): 69. CrossRef
Risk assessment and management of post-transplant diabetes mellitus
Eugene Han, Myoung Soo Kim, Yu Seun Kim, Eun Seok Kang
Metabolism.2016; 65(10): 1559. CrossRef

Review Article

Thyroid
The Diagnosis and Management of Hyperthyroidism in Korea: Consensus Report of the Korean Thyroid Association: Jae Hoon Moon, Ka Hee Yi; Endocrinol Metab. 2013;28(4):275-279. Published online December 12, 2013; DOI: https://doi.org/10.3803/EnM.2013.28.4.275

12,969 View
104 Download
63 Crossref

Abstract PDF PubReader

Hyperthyroidism is one of the causes of thyrotoxicosis and the most common cause of hyperthyroidism in Korea is Graves disease. The diagnosis and treatment of Graves disease are different according to geographical area. Recently, the American Thyroid Association and the American Association of Clinical Endocrinologists suggested new management guidelines for hyperthyroidism. However, these guidelines are different from clinical practice in Korea and are difficult to apply. Therefore, the Korean Thyroid Association (KTA) conducted a survey of KTA members regarding the diagnosis and treatment of hyperthyroidism, and reported the consensus on the management of hyperthyroidism. In this review, we summarized the KTA report on the contemporary practice patterns in the diagnosis and management of hyperthyroidism, and compared this report with guidelines from other countries.

Citations

Citations to this article as recorded by

Competing with the colonial scalpel: ‘Peaceful atoms’ in Cold War Taiwan
Hsiu-Yun Wang
Medical History.2026; : 1. CrossRef
Graves’ Disease and the Risk of Type 2 Diabetes: A Korean Population-Based Study
Yoon Young Cho, Bongseong Kim, Sang-Man Jin, Chan-Hee Jung, Ji Oh Mok, Sun Wook Kim, Jae Hoon Chung, Kyung-Do Han, Tae Hyuk Kim
Thyroid®.2025; 35(1): 60. CrossRef
Quality of guidelines for hyperthyroidism: systematic quality assessment using the AGREE II tool
Yuanshan Wang, Jun Zhang, Xiaoliang Cheng, Xiaoling Duan, Ying Liang, Dali Sun
Postgraduate Medicine.2025; 137(2): 139. CrossRef
Treatment of Graves’ Disease: Faster Remission or Longer but Safe, That Is the Question
Chan-Hee Jung
Endocrinology and Metabolism.2025; 40(1): 70. CrossRef
A Digital Software Support Platform for Hyperthyroidism Management in South Korea: Markov Simulation Model-Based Cost-Effectiveness Analysis
Jung Hyun Kim, Jaeyong Shin, Man S Kim, Jae Hoon Moon
JMIR mHealth and uHealth.2025; 13: e56738. CrossRef
Multiscale Interactome-Guided Discovery Candidate Herbs and Active Ingredients Against Hyperthyroidism by Biased Random Walk Algorithm
Seok-Hoon Han, Ji-Hwan Kim, Yewon Han, Sangjin Kim, Hyowon Jin, Won-Yung Lee
International Journal of Molecular Sciences.2025; 26(19): 9789. CrossRef
Diagnostic Approach and Therapeutic Strategies for Ambiguous Thyrotoxicosis
Mijin Kim
The Korean Journal of Medicine.2025; 100(5): 241. CrossRef
Thyroidectomy in Graves’ Disease With Unusually 4-Fold High Thyroid Hormone Levels: Clinical Challenges and Management
Buseon Kang, In Chang Yoon, Ja Kyung Lee, Hyeong Won Yu, June Young Choi
Journal of Endocrine Surgery.2025; 25(4): 160. CrossRef
Effect of previous administration of potassium iodine and different durations of low iodine diets for radioiodine therapy on the treatment of Graves' disease in iodine-rich areas
Mika Tamura, Kunihiro Nakada, Haruna Iwanaga, Naotoshi Fujita, Katsuhiko Kato
European Journal of Nuclear Medicine and Molecular Imaging.2024; 51(4): 1060. CrossRef
Effects of altitude on thyroid disorders according to Chinese three-rung, ladder-like topography: national cross-sectional study
Boshen Gong, Youmin Wang, Jin-an Zhang, Qiao Zhang, Jiajun Zhao, Jiashu Li, Xichang Wang, Yutong Han, Ziwei Yu, Chenyu Zhang, Bingcong Peng, Yumin Xing, Qiuxian Li, Ping Wang, Yongze Li, Weiping Teng, Zhongyan Shan
BMC Public Health.2024;[Epub] CrossRef
MACE and Hyperthyroidism Treated With Medication, Radioactive Iodine, or Thyroidectomy
Carol Chiung-Hui Peng, Yu-Jie Lin, Sun Y. Lee, Shu-Man Lin, Cheng Han, Ching-Hui Loh, Huei-Kai Huang, Elizabeth N. Pearce
JAMA Network Open.2024; 7(3): e240904. CrossRef
Increased risk of incident gout in patients with hyperthyroidism: a nationwide retrospective cohort study
Ju-Yeun Lee, So-Yeon Park, Seo Young Sohn
Rheumatology International.2023; 44(3): 451. CrossRef
The Current Status of Hyperthyroidism in Korea
Hyemi Kwon
Endocrinology and Metabolism.2023; 38(4): 392. CrossRef
A machine learning-assisted system to predict thyrotoxicosis using patients’ heart rate monitoring data: a retrospective cohort study
Kyubo Shin, Jongchan Kim, Jaemin Park, Tae Jung Oh, Sung Hye Kong, Chang Ho Ahn, Joon Ho Moon, Min Joo Kim, Jae Hoon Moon
Scientific Reports.2023;[Epub] CrossRef
Immunometabolic signatures predict recovery from thyrotoxic myopathy in patients with Graves' disease
Daiki Setoyama, Ho Yeop Lee, Ji Sun Moon, Jingwen Tian, Yea Eun Kang, Ju Hee Lee, Minho Shong, Dongchon Kang, Hyon‐Seung Yi
Journal of Cachexia, Sarcopenia and Muscle.2022; 13(1): 355. CrossRef
Comparison of 99mTc Pertechnetate Thyroid Uptake Rates by Gamma Probe and Gamma Camera Methods for Differentiating Graves’ Disease and Thyroiditis
Meihua Jin, Jonghwa Ahn, Seong-gil Jo, Jangwon Park, Min Ji Jeon, Won Gu Kim, Tae Yong Kim, Won Bae Kim, Young Kee Shong, Jin-Sook Ryu
Nuclear Medicine and Molecular Imaging.2022; 56(1): 42. CrossRef
KSNM60 in Nuclear Endocrinology: from the Beginning to the Future
Chae Moon Hong, Young Jin Jeong, Hae Won Kim, Byeong-Cheol Ahn
Nuclear Medicine and Molecular Imaging.2022; 56(1): 17. CrossRef
Graves’ disease and the risk of Parkinson’s disease: a Korean population-based study
Yoon Young Cho, Bongseong Kim, Dong Wook Shin, Jinyoung Youn, Ji Oh Mok, Chul-Hee Kim, Sun Wook Kim, Jae Hoon Chung, Kyungdo Han, Tae Hyuk Kim
Brain Communications.2022;[Epub] CrossRef
Graves’ Disease and the Risk of End-Stage Renal Disease: A Korean Population-Based Study
Yoon Young Cho, Bongseong Kim, Dong Wook Shin, Hye Ryoun Jang, Bo-Yeon Kim, Chan-Hee Jung, Jae Hyeon Kim, Sun Wook Kim, Jae Hoon Chung, Kyungdo Han, Tae Hyuk Kim
Endocrinology and Metabolism.2022; 37(2): 281. CrossRef
Evaluation and Management of Bone Health in Patients with Thyroid Diseases: a Position Statement from the Korean Thyroid Association
A Ram Hong, Hwa Young Ahn, Bu Kyung Kim, Seong Hee Ahn, So Young Park, Min-Hee Kim, Jeongmin Lee, Sun Wook Cho, Ho-Cheol Kang
International Journal of Thyroidology.2022; 15(1): 1. CrossRef
Patient Population and Test Utilization for Thyroid Function in Local Clinics and Hospitals in Korea
Rihwa Choi, Sang Gon Lee, Eun Hee Lee
Diagnostics.2022; 12(7): 1638. CrossRef
2021 Asia-Pacific Graves’ Disease Consortium Survey of Clinical Practice Patterns in the Management of Graves’ Disease
Rajeev Parameswaran, Mechteld Christine de Jong, James Lee Wai Kit, Kathleen Sek, Tran Quang Nam, Tran Viet Thang, Nguyen Thy Khue, Than Than Aye, Phone Myint Tun, Timothy Cole, Julie A. Miller, Michael Villa, Benjapa Khiewvan, Sirinart Sirinvaravong, Yon
Endocrine.2022; 79(1): 135. CrossRef
Graves’ disease, its treatments, and the risk of atrial fibrillation: A Korean population-based study
Yoon Young Cho, Bongseong Kim, Dughyun Choi, Chul-Hee Kim, Dong Wook Shin, Jee Soo Kim, Seung-Jung Park, Sun Wook Kim, Jae Hoon Chung, Kyungdo Han, Tae Hyuk Kim
Frontiers in Endocrinology.2022;[Epub] CrossRef
Forty Years Together, New Leap Forward! The 40th Anniversary of the Korean Endocrine Society
Jong Chul Won, Ki-Hyun Baek
Endocrinology and Metabolism.2022; 37(6): 851. CrossRef
Evaluation of the role of thyroid scintigraphy in the differential diagnosis of thyrotoxicosis
Carolina M. Perdomo, Marta García‐Goñi, Lidia Sancho, José J. Paricio, María D. Lozano, Magdalena de la Higuera, María Currás, Javier Arbizu, Juan C. Galofré
Clinical Endocrinology.2021; 94(3): 466. CrossRef
Treatment of patients with Graves’ disease in Sweden compared to international surveys of an ‘index patient’
Gabriel Sjölin, Kristina Byström, Mats Holmberg, Ove Törring, Selwan Khamisi, Jan Calissendorff, Mikael Lantz, Bengt Hallengren, Helena Filipsson Nyström, Tereza Planck, Göran Wallin
Endocrinology, Diabetes & Metabolism.2021;[Epub] CrossRef
Secular Trends in Ablation Therapy for Graves’ Disease: An Analysis of a 15-Year Experience at a Tertiary Hospital in South Korea
Min Joo Kim, Ye An Kim, Sun Wook Cho, Su-jin Kim, Kyu Eun Lee, Young Joo Park, Do Joon Park, Bo Youn Cho
Journal of Clinical Medicine.2021; 10(8): 1629. CrossRef
Long-Term Antithyroid Drug Treatment of Graves’ Disease in Children and Adolescents: A 20-Year Single-Center Experience
Ari Song, Su Jin Kim, Min-Sun Kim, Jiyeon Kim, Insung Kim, Ga Young Bae, Eunseop Seo, Young Seok Cho, Joon Young Choi, Sung Yoon Cho, Dong-Kyu Jin
Frontiers in Endocrinology.2021;[Epub] CrossRef
Association of Polygenetic Risk Scores Related to Immunity and Inflammation with Hyperthyroidism Risk and Interactions between the Polygenetic Scores and Dietary Factors in a Large Cohort
Mi Young Song, Sunmin Park, Anjali Mishra
Journal of Thyroid Research.2021; 2021: 1. CrossRef
Treatment Modality and Risk of Heart Failure in Patients With Long-Standing Graves’ Disease: A Nationwide Population-Based Cohort Study
Eyun Song, Mina Kim, Sojeong Park, Min Jeong Park, Jung A. Kim, Eun Roh, Ji Hee Yu, Nam Hoon Kim, Ji A. Seo, Sin Gon Kim, Nan Hee Kim, Kyung Mook Choi, Sei Hyun Baik, Hye Jin Yoo
Frontiers in Endocrinology.2021;[Epub] CrossRef
Risk of Diabetes in Patients with Long-Standing Graves’ Disease: A Longitudinal Study
Eyun Song, Min Ji Koo, Eunjin Noh, Soon Young Hwang, Min Jeong Park, Jung A Kim, Eun Roh, Kyung Mook Choi, Sei Hyun Baik, Geum Joon Cho, Hye Jin Yoo
Endocrinology and Metabolism.2021; 36(6): 1277. CrossRef
Diabetes and Hyperthyroidism: Is There a Causal Link?
Sang Yong Kim
Endocrinology and Metabolism.2021; 36(6): 1175. CrossRef
Incidence and Mortality of Myocardial Infarction and Stroke in Patients with Hyperthyroidism: A Nationwide Cohort Study in Korea
Hyun Jung Kim, Taeuk Kang, Min Ji Kang, Hyeong Sik Ahn, Seo Young Sohn
Thyroid®.2020; 30(7): 955. CrossRef
Diagnosis and Management of Graves’ Disease in Thailand: A Survey of Current Practice
Chutintorn Sriphrapradang
Journal of Thyroid Research.2020; 2020: 1. CrossRef
The success rate of radioactive iodine therapy for Graves’ disease in iodine-replete area and affecting factors: a single-center study
Hyunju Park, Hye In Kim, Jun Park, So Young Park, Tae Hyuk Kim, Jae Hoon Chung, Joon Young Choi, Sun Wook Kim
Nuclear Medicine Communications.2020; 41(3): 212. CrossRef
Tirotoksikoz nedenli erektil disfonksiyon üzerine sildenafil etkisinin histopatolojik olarak değerlendirilmesi
Murat ÖZDEMİR, Canberk TOMRUK, Gürkan YİĞİTTÜRK, Varlık EROL, Emel Öykü ÇETİN, Ilgın YILDIRIM ŞİMŞİR, Çiğdem YENİSEY, Yiğit UYANIKGİL, Adnan ŞİMŞİR, Özer MAKAY
Ege Tıp Dergisi.2020; 59(3): 215. CrossRef
The Management of Thyroid Disease in COVID-19 Pandemic
Won Sang Yoo, Hyun-Kyung Chung
International Journal of Thyroidology.2020; 13(2): 65. CrossRef
Is Hyperthyroidism Diagnosed and Treated Appropriately in the United States?
Ammar Asban, Sophie Dream, Brenessa Lindeman
Advances in Surgery.2019; 53: 117. CrossRef
Long-term remission following antithyroid drug withdrawal in patients with Graves’ hyperthyroidism: parameters with prognostic value
Ricardo V. García-Mayor, Paula Álvarez-Vázquez, Enrique Fluiters, Diana Valverde, Amalia Andrade
Endocrine.2019; 63(2): 316. CrossRef
Safety of long-term antithyroid drug treatment? A systematic review
F. Azizi, R. Malboosbaf
Journal of Endocrinological Investigation.2019; 42(11): 1273. CrossRef
Changes in Thyroid Peroxidase and Thyroglobulin Antibodies Might Be Associated with Graves' Disease Relapse after Antithyroid Drug Therapy
Yun Mi Choi, Mi Kyung Kwak, Sang Mo Hong, Eun-Gyoung Hong
Endocrinology and Metabolism.2019; 34(3): 268. CrossRef
Prevalence and Annual Incidence of Thyroid Disease in Korea from 2006 to 2015: A Nationwide Population-Based Cohort Study
Hyemi Kwon, Jin-hyung Jung, Kyung-Do Han, Yong-Gyu Park, Jung-Hwan Cho, Da Young Lee, Ji Min Han, Se Eun Park, Eun-Jung Rhee, Won-Young Lee
Endocrinology and Metabolism.2018; 33(2): 260. CrossRef
An update in the treatment preference for hyperthyroidism
Obin Kwon
Nature Reviews Endocrinology.2018; 14(7): 438. CrossRef
Clinical Feasibility of Monitoring Resting Heart Rate Using a Wearable Activity Tracker in Patients With Thyrotoxicosis: Prospective Longitudinal Observational Study
Jie-Eun Lee, Dong Hwa Lee, Tae Jung Oh, Kyoung Min Kim, Sung Hee Choi, Soo Lim, Young Joo Park, Do Joon Park, Hak Chul Jang, Jae Hoon Moon
JMIR mHealth and uHealth.2018; 6(7): e159. CrossRef
Graves' Disease Patients with Large Goiters Respond Best to Radioactive Iodine Doses of at Least 15 mCi: a Sonographic Volumetric Study
Yun Ah Jeong, Jee Hee Yoon, Hee Kyung Kim, Ho-Cheol Kang
International Journal of Thyroidology.2018; 11(2): 137. CrossRef
Chylothorax Associated with Substernal Goiter in Graves’ Disease Treated with Radioactive Iodine
Seo Young Oh, Bo Hyun Kim, Do Young Kim, Kyu Min Lee, Min Jin Lee, Sung Su Kim, Jong Ho Kim, Yun Kyung Jeon, Sang Soo Kim, Yong Ki Kim, In Joo Kim
International Journal of Endocrinology and Metabolism.2017;[Epub] CrossRef
Vitiligo and overt thyroid diseases: A nationwide population-based study in Korea
Jung Min Bae, June Hyunkyung Lee, Jae Seung Yun, Byeol Han, Tae Young Han
Journal of the American Academy of Dermatology.2017; 76(5): 871. CrossRef
Increased risk of thyroid diseases in patients with systemic lupus erythematosus: A nationwide population-based Study in Korea
Jae-Seung Yun, Jung Min Bae, Ki-Jo Kim, Yu Seok Jung, Gyong Moon Kim, Hyung-Rae Kim, Jun-Seok Lee, Seung-Hyun Ko, Seon-Ah Cha, Yu-Bae Ahn, Ludmila Prokunina-Olsson
PLOS ONE.2017; 12(6): e0179088. CrossRef
The Second Antithyroid Drug Treatment Is Effective in Relapsed Graves' Disease Patients: A Median 11-Year Follow-Up Study
Ye An Kim, Sun Wook Cho, Hoon Sung Choi, Shinje Moon, Jae Hoon Moon, Kyung Won Kim, Do Joon Park, Ka Hee Yi, Young Joo Park, Bo Youn Cho
Thyroid.2017; 27(4): 491. CrossRef
Free Thyroxine, Anti-Thyroid Stimulating Hormone Receptor Antibody Titers, and Absence of Goiter Were Associated with Responsiveness to Methimazole in Patients with New Onset Graves' Disease
Hoon Sung Choi, Won Sang Yoo
Endocrinology and Metabolism.2017; 32(2): 281. CrossRef
Long-Term Antithyroid Drug Treatment: A Systematic Review and Meta-Analysis
Fereidoun Azizi, Ramin Malboosbaf
Thyroid®.2017; 27(10): 1223. CrossRef
The Recurrence Rate of Graves' Disease among Patients with Subclinical Thyrotoxicosis after Initial Remission with Antithyroid Agents
Myoung Sook Shim, Soo Min Nam, Jin Sae Yoo, Hae Kyung Kim, Sang Jun Lee, Mi Young Lee
International Journal of Thyroidology.2017; 10(2): 77. CrossRef
Serum 25-hydroxyvitamin D might be an independent prognostic factor for Graves disease recurrence
Hwa Young Ahn, Yun Jae Chung, Bo Youn Cho
Medicine.2017; 96(31): e7700. CrossRef
Recent Advances in Autoimmune Thyroid Diseases
Won Sang Yoo, Hyun Kyung Chung
Endocrinology and Metabolism.2016; 31(3): 379. CrossRef
Usefulness of Measuring Thyroid Stimulating Antibody at the Time of Antithyroid Drug Withdrawal for Predicting Relapse of Graves Disease
Hyemi Kwon, Won Gu Kim, Eun Kyung Jang, Mijin Kim, Suyeon Park, Min Ji Jeon, Tae Yong Kim, Jin-Sook Ryu, Young Kee Shong, Won Bae Kim
Endocrinology and Metabolism.2016; 31(2): 300. CrossRef
Hyperthyroidism
Simone De Leo, Sun Y Lee, Lewis E Braverman
The Lancet.2016; 388(10047): 906. CrossRef
Differentiating Graves' disease from subacute thyroiditis using ratio of serum free triiodothyronine to free thyroxine
Chutintorn Sriphrapradang, Adikan Bhasipol
Annals of Medicine and Surgery.2016; 10: 69. CrossRef
Management of hyperthyroid patients in dental emergencies: a case report
Kyung-Jin Lee, Wonse Park, Nan-Sim Pang, Jin-Hyung Cho, Kee-Deog Kim, Bock Young Jung, Eun-Jung Kwak
Journal of Dental Anesthesia and Pain Medicine.2016; 16(2): 147. CrossRef
The Presence of Thyroid-Stimulation Blocking Antibody Prevents High Bone Turnover in Untreated Premenopausal Patients with Graves’ Disease
Sun Wook Cho, Jae Hyun Bae, Gyeong Woon Noh, Ye An Kim, Min Kyong Moon, Kyoung Un Park, Junghan Song, Ka Hee Yi, Do Joon Park, June-Key Chung, Bo Youn Cho, Young Joo Park, Jung-Eun Kim
PLOS ONE.2015; 10(12): e0144599. CrossRef
Refractory Graves' Disease Successfully Cured by Adjunctive Cholestyramine and Subsequent Total Thyroidectomy
Yeoree Yang, Seawon Hwang, Minji Kim, Yejee Lim, Min-Hee Kim, Sohee Lee, Dong-Jun Lim, Moo-Il Kang, Bong-Yun Cha
Endocrinology and Metabolism.2015; 30(4): 620. CrossRef
Improved quality of life in hyperthyroidism patients after surgery
Branka Bukvic, Vladan Zivaljevic, Sandra Sipetic, Aleksandar Diklic, Katarina Tausanovic, Dragos Stojanovic, Dejan Stevanovic, Ivan Paunovic
Journal of Surgical Research.2015; 193(2): 724. CrossRef
Excessive Iodine Intake Does Not Increase the Recurrence Rate of Graves' Disease after Withdrawal of the Antithyroid Drug in an Iodine-Replete Area
Sun Mi Park, Yoon Young Cho, Ji Young Joung, Seo Young Sohn, Sun Wook Kim, Jae Hoon Chung
European Thyroid Journal.2015; 4(1): 36. CrossRef
Brief Review of Articles in 'Endocrinology and Metabolism' in 2013
Won-Young Lee
Endocrinology and Metabolism.2014; 29(3): 251. CrossRef

First
Prev
Page of 1
Next
Last

Search